Literature DB >> 9164972

Concomitant killing in vitro of both gp120-coated CD4+ peripheral T lymphocytes and natural killer cells in the antibody-dependent cellular cytotoxicity (ADCC) system.

A Jewett1, M Cavalcanti, J Giorgi, B Bonavida.   

Abstract

NK cells play an important immunoregulatory role in first line defense mechanisms against infection. As disease progresses, HIV-1 infected patients show loss of NK cytotoxic function, down-modulation and/or loss of expression of both CD16 and CD56 surface Ags on NK cells and a gradual loss of both CD4+ T cells and NK cell numbers. A potential mechanism by which these manifestations may occur in vivo was investigated. We hypothesized that NK-mediated Ab-dependent cellular cytotoxicity (ADCC), using gp120-coated CD4+ peripheral T lymphocytes as targets and anti-HIV serum, will result in the concomitant killing of the CD4+ T lymphocyte targets and the NK lymphocytes. This hypothesis was examined in an in vitro model system. The findings demonstrate that gp120-coated peripheral T lymphocytes can serve as targets and are killed in ADCC. Further, the NK cells that recover from the ADCC reaction show a loss of cytotoxic function, acquire the CD16(dim/-) CD56(dim/-) phenotype and a significant fraction is killed by activation-induced cell death or apoptosis. These findings are reminiscent of the properties of circulating NK cells in HIV-infected patients. The implication of these findings in the pathogenesis of AIDS is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9164972

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation.

Authors:  C-C Tang; G Isitman; J Bruneau; C Tremblay; N F Bernard; S J Kent; M S Parsons
Journal:  Clin Exp Immunol       Date:  2015-06-07       Impact factor: 4.330

2.  NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors.

Authors:  Alexander W MacFarlane; Mowafaq Jillab; Mitchell R Smith; R Katherine Alpaugh; Marion E Cole; Samuel Litwin; Michael M Millenson; Tahseen Al-Saleem; Adam D Cohen; Kerry S Campbell
Journal:  Oncoimmunology       Date:  2017-05-19       Impact factor: 8.110

3.  Expression of killer inhibitory receptors on cytotoxic cells from HIV-1-infected individuals.

Authors:  M D Galiani; E Aguado; R Tarazona; P Romero; I Molina; M Santamaria; R Solana; J Peña
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

4.  The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.

Authors:  Tatiana Pazina; Ashley M James; Alexander W MacFarlane; Natalie A Bezman; Karla A Henning; Christine Bee; Robert F Graziano; Michael D Robbins; Adam D Cohen; Kerry S Campbell
Journal:  Oncoimmunology       Date:  2017-06-16       Impact factor: 8.110

5.  Osteonecrosis of the Jaw Developed in Mice: DISEASE VARIANTS REGULATED BY γδ T CELLS IN ORAL MUCOSAL BARRIER IMMUNITY.

Authors:  Sil Park; Keiichi Kanayama; Kawaljit Kaur; Han-Ching Helen Tseng; Sina Banankhah; Davood Talebi Quje; James W Sayre; Anahid Jewett; Ichiro Nishimura
Journal:  J Biol Chem       Date:  2015-05-26       Impact factor: 5.157

6.  Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection.

Authors:  Qingquan Liu; Yongtao Sun; Suzannah Rihn; Anne Nolting; Peter Nicholas Tsoukas; Stephanie Jost; Kristen Cohen; Bruce Walker; Galit Alter
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

7.  Slow turnover of HIV-1 receptors on quiescent CD4+ T cells causes prolonged surface retention of gp120 immune complexes in vivo.

Authors:  Yasuhiro Suzuki; Hiroyuki Gatanaga; Natsuo Tachikawa; Shinichi Oka
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.